Literature DB >> 22959135

Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes.

Daniel Rocha Carvalho1, Guilherme Dotto Brand, Jaime Moritz Brum, Reinaldo Issao Takata, Carlos Eduardo Speck-Martins, Riccardo Pratesi.   

Abstract

Hyperargininemia (HA) is an autosomal recessive disease that typically has a clinical presentation that is distinct from other urea cycle disorders. It is caused by the deficient activity of the enzyme arginase I, encoded by the gene ARG1. We screened for ARG1 mutations and measured erythrocyte enzyme activity in a series of 16 Brazilian HA patients. Novel mutations, in addition to previously described missense mutations, were analysed for their effect on the structure, stability and/or function of arginase I (ARG1) using bioinformatics tools. Three previously reported mutations were found (p.R21X; p.I11T and p.W122X), and five novel mutations were identified (p.G27D; p.G74V; p.T134I; p.R308Q; p.I174fs179). The p.T134I mutation was the most frequent in the Brazilian population. Patients carrying the p.R308Q mutation had higher residual ARG1 decreased activity, but presented no distinguishable phenotype compared to the other patients. Bioinformatics analyses revealed that missense mutations (1) affect the ARG1 active site, (2) interfere with the stability of the ARG1 folded conformation or (3) alter the quaternary structure of the ARG1. Our study reinforced the role of Arg308 residue for assembly of the ARG1 homotrimer. The panel of heterogeneous ARG1 mutations that cause HA was expanded, nevertheless a clear genotype-phenotype correlation was not observed in our series.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959135     DOI: 10.1016/j.gene.2012.08.003

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

Review 1.  Arginase-1 deficiency.

Authors:  Yuan Yan Sin; Garrett Baron; Andreas Schulze; Colin D Funk
Journal:  J Mol Med (Berl)       Date:  2015-10-14       Impact factor: 4.599

2.  Arginase I mRNA therapy - a novel approach to rescue arginase 1 enzyme deficiency.

Authors:  Kirtika H Asrani; Lei Cheng; Christopher J Cheng; Romesh R Subramanian
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

3.  Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency.

Authors:  Suhail Khoja; Xiao-Bo Liu; Brian Truong; Matthew Nitzahn; Jenna Lambert; Adam Eliav; Eram Nasser; Emma Randolph; Kristine E Burke; Rebecca White; Xuling Zhu; Paolo G V Martini; Itzhak Nissim; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-27       Impact factor: 10.183

4.  Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.

Authors:  Jennifer Kasten; Chuhong Hu; Ragini Bhargava; Hana Park; Denise Tai; James A Byrne; Bart Marescau; Peter P De Deyn; Lisa Schlichting; Wayne W Grody; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2013-07-06       Impact factor: 4.797

5.  Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency.

Authors:  George A Diaz; Andreas Schulze; Markey C McNutt; Elisa Leão-Teles; J Lawrence Merritt; Gregory M Enns; Spyros Batzios; Allison Bannick; Roberto T Zori; Leslie S Sloan; Susan L Potts; Gillian Bubb; Anthony G Quinn
Journal:  J Inherit Metab Dis       Date:  2021-01-26       Impact factor: 4.982

6.  Novel and de novo mutations in pediatric refractory epilepsy.

Authors:  Jing Liu; Lili Tong; Shuangshuang Song; Yue Niu; Jun Li; Xiu Wu; Jie Zhang; Clement C Zai; Fang Luo; Jian Wu; Haiyin Li; Albert H C Wong; Ruopeng Sun; Fang Liu; Baomin Li
Journal:  Mol Brain       Date:  2018-09-05       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.